IMR Press / FBL / Volume 26 / Issue 12 / DOI: 10.52586/5055
Open Access Review
CARD9 as a potential therapeutic target in lung cancer
Show Less
1 Department of Emergency Medicine and Intensive Care, Shanghai Songjiang District Central Hospital, 201600 Shanghai, China
2 Department of Emergency Medicine and Intensive Care, Shanghai Songjiang Clinical Medical College of Nanjing Medical University, 201600 Shanghai, China
3 Department of Pharmacy, Shanghai Songjiang District Central Hospital, 201600 Shanghai, China

Academic Editor: Chuanjin Wu

Front. Biosci. (Landmark Ed) 2021, 26(12), 1621–1626; https://doi.org/10.52586/5055
Submitted: 28 August 2021 | Revised: 17 November 2021 | Accepted: 19 November 2021 | Published: 30 December 2021
(This article belongs to the Special Issue Cancer Metabolism and the Tumor Microenvironment)
Copyright: © 2021 The Author(s). Published by BRI.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

Caspase recruitment domain-containing protein 9 (CARD9) is highly expressed in myeloid cells and has been identified as a central regulator of innate immunity. Increasingly, studies demonstrate that CARD9 also plays a critical role in the development of lung cancer. This review focuses on the clinical significance and potential molecular mechanisms that CARD9 plays in lung cancer.

Keywords
CARD9
Lung cancer
Clinical significance
Molecular mechanism
Therapy target
Figures
Fig. 1.
Share
Back to top